Abstract: A storage apparatus includes a storage device having a first storage assembly with a plurality of first storage racks and a second storage assembly with a plurality of second storage racks surrounding the first storage racks. At least one of the first and second storage assemblies includes a removable carrier rack configured to align with a selected storage rack of the other first or second storage assembly. A protective cover device includes first and second protective cover assemblies respective disposed on top ends of the first and second storage assemblies. At least one of the first and second protective cover assemblies is openable at an area corresponding to the top of the carrier rack to permit removal of the same.

Abstract: A serum-free culture medium for hematopoietic stem cell (HSC) expansion is provided. The serum-free culture medium includes a serum-free base medium, cytokines, an umbilical cord mesenchymal stem cell conditioned medium and supplemental components. The cytokines comprise stem cell factor, thrombopoietin and hematopoietic growth factor Flt3 ligand. The umbilical cord mesenchymal stern cell conditioned medium is derived from culturing human umbilical cord mesenchymal stem cells. The supplemental components comprise vitamin C, vitamin E or a combination of vitamin C and vitamin E.

Abstract: A method for cryopreserving an umbilical cord tissue strip includes the steps of: (a) applying tension to a segment of an umbilical cord to expand spaces between umbilical cord vessels; (b) cutting the segment of the umbilical cord, at the spaces between the umbilical cord vessels in a longitudinal direction that parallels a length of the umbilical cord vessels, to obtain the umbilical cord tissue strip, wherein the umbilical cord tissue strip contains Wharton's jelly from a perivascular region, a intervascular region, and a subamnion region; (c) incubating the umbilical cord tissue strip with a cryogenic composition; and (d) cryopreserving the umbilical cord tissue strip containing the Wharton's jelly and the cryogenic composition.

Abstract: A method for cryopreserving an umbilical cord tissue strip includes the steps of: (a) applying tension to a segment of an umbilical cord to expand spaces between umbilical cord vessels; (b) cutting the segment of the umbilical cord, at the spaces between the umbilical cord vessels in a longitudinal direction that parallels a length of the umbilical cord vessels, to obtain the umbilical cord tissue strip, wherein the umbilical cord tissue strip contains Wharton's jelly from a perivascular region, a intervascular region, and a subamnion region; (c) incubating the umbilical cord tissue strip with a cryogenic composition; and (d) cryopreserving the umbilical cord tissue strip containing the Wharton's jelly and the cryogenic composition.

Abstract: An automatic handle assembly for scissors-shearing is a handy device for fixing a scissors to cut tissue, which comprises: a fixture portion including: a fix scissor handle having a proximal end and a distal end, the proximal end equipped with a fix tenon and the distal end equipped with a connection portion; a free scissor handle having a distal end and a proximal end coupled to the fix tenon causing the distal end of the free scissor handle and the distal end of the fix scissor handle to pivot to close or open; and a pair of fixture elements being mounted on the fix scissor handle and the free scissor handle, and slidably moving along with the fix scissor handle and the free scissor handle for adjustably fixing a scissors; a drive unit coupled to the fixture portion to provide reciprocating motion of the free scissor handle to the fix scissor handle; and a power unit being removably equipped on the distal end of the fix scissor handle, and coupled to the drive unit to provide power for the reciprocating mot

Abstract: A method for inhibiting growth and/or metastasis of a tumor in a mammal is disclosed. The method comprises administering to a mammal in need thereof an effective amount of stem cells comprising a transgene encoding at least one oncogenic protein, wherein the stem cells are immortal and show no signs of neoplastic transformation; and administering to the mammal a vaccine composition comprising an effective amount of at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one oncogenic protein, and thereby inhibiting growth and/or metastasis of a tumor in the mammal. A therapeutic kit for inhibiting growth and/or metastasis of a tumor in a mammal is also disclosed.

Abstract: A method of preserving an umbilical cord is disclosed. The method comprises obtaining a segment of an umbilical cord; mincing the segment of the umbilical cord into cord tissue pieces; admixing the cord tissue pieces with a cryogenic composition comprising a cryoprotectant and a protein to form a mixture; shaking the mixture for a duration of no shorter than 20 minutes and no longer than 40 minutes; and cryopreserving the mixture.

Abstract: A method of preserving an umbilical cord is disclosed. The method comprises obtaining a segment of an umbilical cord; mincing the segment of the umbilical cord into cord tissue pieces; admixing the cord tissue pieces with a cryogenic composition comprising a cryoprotectant and a protein to form a mixture; shaking the mixture for a duration of no shorter than 20 minutes and no longer than 40 minutes; and cryopreserving the mixture.

Abstract: A storage-access apparatus includes a first support device including a first base; at least one first storage-access device and at least one first storage device, disposed on the first base and arranged in a first circle; a second support device including a second base; at least one second storage-access device and at least one second storage device, disposed on the second base and arranged in a second circle; and a transporting device, wherein the first storage-access device, the first storage device, the second storage-access device and the second storage device each has plural compartments, the transporting device corresponds to the compartments, and the first storage-access device and the first storage device can rotate relative to the second storage-access device and the second storage device. Accordingly, the storage-access apparatus can be employed in depositing and picking up products independently. Also disclosed is a storage system including, among others, the storage-access apparatus.

Abstract: A method for treating HIV infection is disclosed. The method comprises administering to a patient in need thereof a therapeutically effective amount of a fusion protein comprising: a) a Pseudomonas Exotoxin A (PE) peptide comprising a binding domain and a PE translocation domain, the PE peptide being devoid of cytotoxic domain III; b) optionally gag24, being fused to the PE peptide; c) a fragment of gp120 C1 domain, being fused to the PE peptide or fused to the gag24 if the gag24 is present; d) a fragment of gp 120 C5 domain, being fused to the fragment of gp120 C1 domain; e) a fragment of gp41 amino acid sequence, being fused to the fragment of gp 120 C5 domain, and f) optionally an endoplasmic reticulum retention sequence, being fused to the C-terminus of the fragment of gp41.

Abstract: The present invention relates to a storage apparatus, including: a base; an axle unit, supported on the base; a first storage-access unit and a plurality of storage units of which the bottoms correspond to the base and arranged in a first circle; a plurality of second storage units of which the bottoms correspond to the base and arranged in a second circle; a first rotating unit connected with the tops of the first storage units; a first cover unit connected with the tops of the second storage units; and a plurality of first rolling units connected with the first rotating unit, wherein the first storage-access unit and the first storage units can rotate relative to the second storage units. Accordingly, the storage apparatus of the present invention can be employed in storing and accessing the products independently.

Abstract: A method for inhibiting growth and/or metastasis of a tumor in a mammal is disclosed. The method comprises administering to a mammal in need thereof an effective amount of stem cells comprising a transgene encoding at least one oncogenic protein, wherein the stem cells are immortal and show no signs of neoplastic transformation, and administering to the mammal a vaccine composition comprising an effective amount of at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one oncogenic protein, and thereby inhibiting growth and/or metastasis of a tumor in the mammal. A therapeutic kit for inhibiting growth and/or metastasis of a tumor in a mammal is also disclosed.

Abstract: The present invention relates to a storage apparatus, including: a base; an axle unit, supported on the base; a first storage-access unit and a plurality of storage units of which the bottoms correspond to the base and arranged in a first circle; a plurality of second storage units of which the bottoms correspond to the base and arranged in a second circle; a first rotating unit connected with the tops of the first storage units; a first cover unit connected with the tops of the second storage units; and a plurality of first rolling units connected with the first rotating unit, wherein the first storage-access unit and the first storage units can rotate relative to the second storage units. Accordingly, the storage apparatus of the present invention can be employed in storing and accessing the products independently.

Abstract: The present invention relates to a super-antigen fusion protein, comprising: a peptide fragment whose sequence corresponds to a partial SARS E2 spike protein; and a translocating peptide fragment for transporting a protein into a cell and translocating the protein in cytosol; wherein, the amino acid sequence of the peptide fragment corresponding to the partial SARS E2 spike protein includes SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4. The present invention further relates to DNA sequences corresponding to the partial SARS E2 spike protein includes SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, or SEQ ID NO. 8; wherein the DNA sequences are able to express specific proteins in an E. Coli expression system.

Abstract: Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.

Abstract: A chimeric fusion protein useful as an immunogen for inducing HIV antigen-specific immune responses contains a first polypeptidyl region and a second polypeptidyl region. The first polypeptidyl region includes a Pseudomonas Exotoxin A (PE) binding domain and a PE translocation domain. The second polypeptidyl region includes (i) a first peptidyl segment containing a fragment of gp120 C1 domain, located at the N-terminus of the second peptidyl region; (ii) a second peptidyl segment containing a fragment of gp120 C5 domain, located at the C-terminus of the first peptidyl segment; and (iii) a third peptidyl segment containing a fragment of gp41, located at the C-terminus of the second peptidyl segment. The second polypeptidyl region contains an antigenic determinant specific to one subtype of HIV. An intermediate polypeptide containing a non-Env, HIV antigenic determinant selected from Gag24, Nef, Tat and Rev may be included.

Abstract: A storage-access apparatus includes a first support device including a first base; at least one first storage-access device and at least one first storage device, disposed on the first base and arranged in a first circle; a second support device including a second base; at least one second storage-access device and at least one second storage device, disposed on the second base and arranged in a second circle; and a transporting device, wherein the first storage-access device, the first storage device, the second storage-access device and the second storage device each has plural compartments, the transporting device corresponds to the compartments, and the first storage-access device and the first storage device can rotate relative to the second storage-access device and the second storage device. Accordingly, the storage-access apparatus can be employed in depositing and picking up products independently. Also disclosed is a storage system including, among others, the storage-access apparatus.

Abstract: Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a Pseudomonas Exotoxin A (PE) vector to obtain a chimeric gene plasmid, and expressing the chimeric gene plasmid in a host cell to obtain the chimeric vaccinal virus antigen. The PE vector contains a PE fragment, which has a binding domain and a translocating domain, and a carboxyl terminal moiety, which includes an endoplasmic reticulum retention sequence. The DNA fragment encoding the selected segment of the virus protein is inserted between the PE fragment and the carboxyl terminal moiety.

Abstract: A fusion protein of porcine reproductive and respiratory syndrome virus (PRRSV) for PRRSV vaccine. The fusion protein includes: (a) a Pseudomoitas Exoloxin A (PE) peptide that comprises a binding domain and a translocating domain; (b) a peptide fragment that contains a N-terminal portion of PRRSV ORF6 protein; (c) a peptide fragment that has a N-terminal portion of PRRSV ORF5 protein; and (d) a carboxyl terminal domain that comprises an amino acid seciuence KDEL. The PE peptide is located at the N-terminus of the fusion protein, and the peptide fraament containinC the N-terminal portion of PRRSV ORF5 protein is located between the peptide fragment containing the N-terminal portion of PRRSV ORF6 protein and the carboxyl terminal domain.

Abstract: Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.